SOLIRIS (eculizumab): The first treatment specifically approved for PNH

Taking SOLIRIS

Is SOLIRIS right for me?

SOLIRIS® (eculizumab) is given as an IV infusion at the doctor's office or a special infusion center. The infusion usually lasts about 35 minutes.

SOLIRIS (eculizumab)You will receive your SOLIRIS infusion once a week for the first 4 weeks (600-mg induction dose). Beginning on the 5th week, you will receive a slightly higher dosage of SOLIRIS every two weeks (900-mg maintenance dose).

For best results

  • It's important not to miss any treatments. SOLIRIS only controls hemolysis as long as you take it
     
  • Make sure your doctor knows about any other drugs you are taking
     
  • Talk with your doctor before you take any vitamins, over-the-counter drugs, or natural supplements, as these may affect your therapy as well

Taking SOLIRISTo find out how to begin SOLIRIS therapy and how the OneSource™ Program will guide you each step of the way, please contact an Alexion Case Manager at OneSource.

OneSource is a team of registered nurses at Alexion dedicated to assisting you with your questions about SOLIRIS treatment. This team is available to help facilitate medical insurance coverage and funding options.

Next: Side Effects

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.